Locating food sovereignty: geographical and sectoral distance in the global food system

This paper seeks to problematize the role of local food systems within the food sovereignty movement and as a counter to the logic of the global industrial food system. It answers the question of how food sovereignty, via its tenet of local food systems, addresses the geographical and sectoral distances in the global food system. In doing this, it utilizes an approach loosely based on Chayanovian thinking and analytical tools provided through food regime analysis, the theory of uneven geographical development and the metabolic rift. The paper explores six forms of distance in the industrial food system – production from consumption, distant markets, peasants from their land, producers from consumers, the rural-urban divide and agriculture from nature. Then the paper situates local food systems within food sovereignty and food sovereignty within the wider transnational agrarian movements from which it emerged. Next the paper differentiates local food systems by scale, method and character. Finally, it illustrates how and to what extent food sovereignty counters these distances by evaluating the abilities and gaps of food sovereignty in relation to the various forms of distance

Estimating the Relevant Source Area of Pollen in the past cultural landscapes of southern Sweden -- A forward modelling approach

International audienceMiddle and Late Holocene in southern Sweden, in order to explore the possible effects of past changes in vegetation composition, openness and structure in terms of patch size and spatial distribution. The RSAP of small basins (bogs or lakes) in the past has to be estimated if quantitative reconstruction of past vegetation at the local spatial scale is to be achieved using Sugita's Landscape Reconstruction Algorithm (LRA). In this study we apply a forward modelling approach to estimate past RSAP using the computer simulation model HUMPOL. The landscape designs are based on past landscape maps produced using a combination of palaeobotanical, archaeological and historical data, and the area's geology and soil characteristics. Four time windows characterised by different landscape/land-use were selected, i.e. Early Neolithic, Late Bronze Age, Viking Age, and Middle Ages. We found that RSAP estimates for hypothetical past landscapes in Skåne differ by ca. 600 m to 1200 m between the selected time periods, whatever the size of the basin (lake or bog, 25- 250 m radius). The most probable explanation for the differences in RSAP between time slices is variable patch size and spatial distribution of patches in the landscape. The RSAPs vary between ca. 1200 and 2300 m for small basins (25 m and 70 m radius), and between ca. 2000 and 3000 m for larger basins (250 m radius). These values are within the range of earlier estimates of modern and past RSAPs for southern Scandinavia obtained using simulated or empirical data. These results suggest that, given the type of setting of that region in terms of taxa composition and traditional land-use, the RSAP for small-size lakes (25-250 m radius) will generally be in the range ca. 1200-3000 m. The forward modelling approach is found to be useful to assess the possible effects on RSAP of changes in vegetation/landscape characteristics between different periods of the past. Moreover, comparison of RSAP estimates obtained using both the forward and backward modelling approaches will be important to identify the most credible RSAP estimates for the past

Influence of Quince rootstocks on Entomosporium Leaf Spot (Entomosporium mespili) susceptibility in European Pear cv. Abate Fetel

Entomosporium leaf spot (ELS) is caused by the fungus Fabraea maculata (anamorph: Entomosporium mespili) and affects most pear cultivars and quince rootstocks in Brazil. The aim of this study was to characterize the effect of Adams, EMA and EMC quince rootstocks on ELS in European pear cultivar “Abate Fetel” in Southern Brazil, during the 2009/2010, 2010/2011 and 2011/2012 growing season. The incidence and severity of disease was quantified weekly in 100 randomly leaves distributed in four medium-height branches per plant with eight replications. Disease progress curves of ELS were constructed and the epidemics compared according to: (1) the beginning of symptoms appearance (BSA); (2) the time to reach the maximum disease incidence and severity (TRMDI and TRMDS); (3) area under the incidence and severity disease progress curve (AUIDPC and AUSDPC). The data were analyzed by linear regression and adjusted for three empirical models: Logistic, Monomolecular and Gompertz. The Abate Fetel cultivar under all rootstocks evaluated was susceptible to E. mespili. However, there were significant differences in ELS intensity among rootstocks evaluated. The highest ELS intensities were observed in combinations with EMA and Adams quince rootstock. Abate Fetel cultivar grafted on EMC quince rootstock showed all epidemiological variables results significantly different when compared with EMA quince rootstock. EMC quince rootstock induced late resistance compared with the other considerated rootstocks. The Logistic model was the most appropriates to describe the ELS progress of Abate Fetel cultivar under all rootstocks evaluated in the edafoclimatic conditions of Southern Brazil, during the 2009/2010, 2010/2011 and 2011/2012 growing season

Arbitrary rotation and entanglement of flux SQUID qubits

We propose a new approach for the arbitrary rotation of a three-level SQUID qubit and describe a new strategy for the creation of coherence transfer and entangled states between two three-level SQUID qubits. The former is succeeded by exploring the coupled-uncoupled states of the system when irradiated with two microwave pulses, and the latter is succeeded by placing the SQUID qubits into a microwave cavity and used adiabatic passage methods for their manipulation.Comment: Accepted for publication in Phys. Rev.

PRECISE - pregabalin in addition to usual care for sciatica: Study protocol for a randomised controlled trial

Background: Sciatica is a type of neuropathic pain that is characterised by pain radiating into the leg. It is often accompanied by low back pain and neurological deficits in the lower limb. While this condition may cause significant suffering for the individual, the lack of evidence supporting effective treatments for sciatica makes clinical management difficult. Our objectives are to determine the efficacy of pregabalin on reducing leg pain intensity and its cost-effectiveness in patients with sciatica.Methods/Design: PRECISE is a prospectively registered, double-blind, randomised placebo-controlled trial of pregabalin compared to placebo, in addition to usual care. Inclusion criteria include moderate to severe leg pain below the knee with evidence of nerve root/spinal nerve involvement. Participants will be randomised to receive either pregabalin with usual care (n = 102) or placebo with usual care (n = 102) for 8 weeks. The medicine dosage will be titrated up to the participant's optimal dose, to a maximum 600 mg per day. Follow up consultations will monitor individual progress, tolerability and adverse events. Usual care, if deemed appropriate by the study doctor, may include a referral for physical or manual therapy and/or prescription of analgesic medication. Participants, doctors and researchers collecting participant data will be blinded to treatment allocation. Participants will be assessed at baseline and at weeks 2, 4, 8, 12, 26 and 52. The primary outcome will determine the efficacy of pregabalin in reducing leg pain intensity. Secondary outcomes will include back pain intensity, disability and quality of life. Data analysis will be blinded and by intention-to-treat. A parallel economic evaluation will be conducted from health sector and societal perspectives.Discussion: This study will establish the efficacy of pregabalin in reducing leg pain intensity in patients with sciatica and provide important information regarding the effect of pregabalin treatment on disability and quality of life. The impact of this research may allow the future development of a cost-effective conservative treatment strategy for patients with sciatica.Trial registration: ClinicalTrial.gov, ACTRN 12613000530729

CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential

Although early stage ovarian cancer can be effectively treated with surgery and chemotherapy, the majority of cases present with advanced disease, which remains essentially incurable. Unfortunately, little is known about the genes important for the development and progression of this disease. In this study, the expression of 68 phosphatases was determined in immortalized ovarian epithelial cells (IOSE) and compared to ovarian cancer cell lines. CL100, a dual specificity phosphatase, displayed 10-25-fold higher expression in normal compared to malignant ovarian cell lines. Immunohistochemical staining of normal ovaries and 68 ovarian cancer specimens confirmed this differential expression. Re-expression of CL100 in ovarian cancer cells decreased adherent and non-adherent cell growth and induced phenotypic changes including loss of filopodia and lamellipodia with an associated decrease in cell motility. Induced expression of CL100 in ovarian cancer cells suppressed intraperitoneal tumor growth in nude mice. These results show for the first time that CL100 expression is altered in human ovarian cancer, that CL100 expression changes cell morphology and motility, and that it suppresses intraperitoneal growth of human ovarian epithelial cancer. These data suggest that down-regulation of CL100 may play a role in the progression of human ovarian cancer

PRECISE - pregabalin in addition to usual care: Statistical analysis plan

Background: Sciatica is a severe, disabling condition that lacks high quality evidence for effective treatment strategies. This a priori statistical analysis plan describes the methodology of analysis for the PRECISE study. Methods/design: PRECISE is a prospectively registered, double blind, randomised placebo controlled trial of pregabalin compared to placebo, in addition to usual care in patients with sciatica. The aim of this study is to determine the efficacy and cost-effectiveness of pregabalin in reducing leg pain intensity (primary outcome). Secondary outcomes include disability (key secondary), back pain intensity, quality of life, participants' perceived global effect, work absenteeism and health utilisation. Information about medication usage and tolerability are also collected. Outcomes are collected over one year (weeks 2, 4, 8, 12, 26 and 52). Double data entry will be conducted for primary and key secondary outcomes. Other outcomes will be checked using a risk-based approach. Analyses will be consistent with the intention-to-treat principle. Statistical tests will be two-tailed with a p value <0.05 considered significant. Group allocation will remain masked until analyses and interpretation are finalised. Repeated-measure linear mixed models will assess the effect of treatment (pregabalin versus placebo) on primary and secondary outcomes at all time points. Fixed effects will include group allocation, visit as a categorical variable and the interaction between group and visit. Covariates will include baseline leg pain and symptom duration, with an interaction term between baseline leg pain and visit. Pairwise differences between groups will be tested at weeks 8 and 52. The number of serious adverse events and adverse events will be reported, and the proportion of patients per group who have at least one event will be compared using Fisher's exact test. An economic evaluation will be conducted if there is a treatment effect on the primary outcome at week 8. A subgroup analysis will assess whether presenting features of neuropathic pain at baseline modify the treatment effect of leg pain at week 8. Discussion: This statistical analysis plan provides detailed methodology for the analysis of the PRECISE study, which aims to deliver much needed evidence about effective and affordable management of sciatica. Trial registration: Australian and New Zealand Clinical Trials Registry ( ACTRN12613000530729. Registered 13 May 2013

A randomized controlled trial of home visits by neighborhood mentor mothers to improve children's nutrition in South Africa

Malnourished children and babies with birth weights under 2500 g are at high risk for negative outcomes over their lifespans. Philani, a paraprofessional home visiting program, was developed to improve nutritional outcomes for young children in South Africa. One “mentor mother” was recruited from each of 37 neighborhoods in Cape Town, South Africa. Mentor mothers were trained to conduct home visits to weigh children under six years old and to support mothers to problem-solve life challenges, especially around nutrition. Households with underweight children were assigned randomly on a 2:1 ratio to the Philani program (n = 500) or to a standard care condition (n = 179); selection effects occurred and children in the intervention households weighed less at recruitment. Children were evaluated over a one-year period (n = 679 at recruitment and n = 638 with at least one follow-up; 94%). Longitudinal random effects models indicated that, over 12 months, the children in the intervention condition gained significantly more weight than children in the control condition. Mentor mothers who are positive peer deviants may be a viable strategy that is efficacious and can build community, and the use of mentor mothers for other problems in South Africa is discussed

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study

Background. CheckMate 040 assessed the efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma (HCC). Understanding the safety profile of nivolumab is needed to support the management of treatment-related adverse events (TRAEs). This analysis assessed the safety of nivolumab monotherapy in the phase I/II, open-label CheckMate 040 study. Materials and Methods. Select TRAEs (sTRAEs; TRAEs with potential immunologic etiology requiring more frequent monitoring) occurring between first dose and 30 days after last dose were analyzed in patients in the dose-escalation and -expansion phases. Time to onset (TTO), time to resolution (TTR), and recurrence of sTRAEs were assessed, and the outcome of treatment with immune-modulating medication (IMM) was evaluated. Results. The analysis included 262 patients. The most common sTRAE was skin (35.5%), followed by gastrointestinal (14.5%) and hepatic (14.1%) events; the majority were grade 1/2, with 10.7% of patients experiencing grade 3/4 events. One patient had grade 5 pneumonitis. Median (range) TTO ranged from 3.6 (0.1–59.9) weeks for skin sTRAEs to 47.6 (47.1–48.0) weeks for renal sTRAEs. Overall, 68% of sTRAEs resolved, with median (range) TTR ranging from 3.7 (0.1–123.3+) weeks for gastrointestinal sTRAEs to 28.4 (0.1–79.1) weeks for endocrine sTRAEs. Most gastrointestinal and all hepatic events resolved with treatment in accordance with established toxicity management algorithms. In 57 patients (40%), sTRAEs were managed with IMM. Reoccurrence of sTRAEs was uncommon following rechallenge with nivolumab. Conclusion. Nivolumab demonstrated a manageable safety profile in this analysis of patients with advanced HCC. A majority of sTRAEs resolved with treatment